Skip to main content

Change to Macrolide Preferred Drug List Prior Authorization Duration Set for September 15, 2020

Last updated on 8/7/2020

On September 15, 2020, the Vendor Drug Program will extend the non-preferred prior authorization duration for macrolides from 30 days to 90 days for people with diagnosis of Gastroparesis, Cerebral Palsy Gastroparesis, or Gastroesophageal reflux disease (GERD) Gastrostomy complications. This will accommodate longer-term prescribing for such conditions.

Managed care organizations are required to comply with these Preferred Drug List (PDL) prior authorization criteria, including duration.

Change will be reflected on the Preferred Drug List and Preferred Drug List Criteria Guide in September.

Contact with comments or any questions.